Golimumab is Witnessing High Growth in the Global TNF Alpha Inhibitors Market

 
 
Spread the Word
Listed Under

Tag:
InfoholicResearch

Industry:
Reports

Location:
Bangalore - Karnataka - India

Subject:
Reports

BANGALORE, India - Sept. 12, 2019 - PRLog -- With its recently published study "Global TNF Alpha Inhibitors Market Drivers, Restraints, Opportunities, Trends, and Forecast up to 2025", Infoholic Research forecasts that the global TNF alpha inhibitors market will continue to grow, owing to increased spending on R&D by pharmaceutical companies, higher prevalence of chronic autoimmune diseases globally, and constant research to develop target-based biologics. Continuous development of biosimilars and evolving market opportunities are poised to support the market growth during the forecast period 2019–2025.

The global TNF alpha inhibitors market, by drug class, is segmented into adalimumab, certolizumab pegol, etanercept, golimumab, and infliximab. Among these, adalimumab occupied a dominant share in 2018, and golimumab is expected to grow at a high CAGR during the forecast period 2019–2025. Increased clinical efficacy and high preference by physicians for the treatment of severe rheumatic diseases made adalimumab the largest revenue contributor in 2018. Currently, many companies are heavily investing to develop innovative products and enjoy the first-mover's advantage in the market; this will be crucial at a point as soon as biologics lose their patents. Adalimumab has the highest number of ongoing clinical trials among various TNF alpha inhibitors, followed by certolizumab pegol.

Access Full Report Summary @ https://www.infoholicresearch.com/report/tnf-alpha-inhibitors-market

North America occupied a significant share in the TNF alpha inhibitors market in 2018, and Europe is also likely to grow at a high CAGR during the forecast period. Many companies, including Amgen, have filed the majority of their patents in the US, which provides them more extended exclusivity in North America. Growing R&D investments to develop new drugs and increasing efforts to accept biosimilars further make Europe the fastest-growing region.

Visit Infoholic Research (https://www.infoholicresearch.com/) website for complete or sample report.

Contact
Infoholic Research LLP
inquiry@infoholicresearch.com
08046151400
End
Email:***@infoholicresearch.com
Tags:InfoholicResearch
Industry:Reports
Location:Bangalore - Karnataka - India
Subject:Reports
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Infoholic Research LLP PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share